

### CanBas raised \$20 million in the 4th financing



CanBas Co., Ltd. ("CanBas"), a privately held drug discovery company located in Numazu-city, Shizuoka, Japan, announced today that the company has raised approximately \$20 million (JPY 2,359 million) in the 4th financing.

This round, which closed November 30, 2005, was co-led by NIF SMBC Ventures and MVC (Mitsui Ventures). 24 other VC firms and 8 strategic investors, including Nikko antfactory, MBL Venture Capital, Mizuho Capital, Nomura Securities and Marubeni, participated in this round.

#### About CanBas

CanBas was spun off of the research of three scientists from the Nagoya City Medical School and Fujita Health Medical School. These scientists founded CanBas as a drug development biotech with help by Angels and Venture Capitalists in 2000.

CanBas's core technologies include drugs that target the G2 checkpoint and a screening system to find selective blockers of the G2 checkpoint.

The company's leading compound CBP501 is currently under investigation in Phase I clinical trial in the United States as the world's first G2 checkpoint blocker.

CanBas is also developing techniques to best determine the specific drug sensitivity of individual cancers from a patient, to increase the probability of prescribing a successful drug regime.

For more information about CanBas, please visit [www.canbas.co.jp](http://www.canbas.co.jp).

#### Company Contact

Masashi Suganuma, M.D., Ph.D.  
Executive Vice President & COO  
Phone: +81-55-954-3666  
Fax: +81-55-954-3668  
or >> [Contact form](#)